Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF) (DECAF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01751607|
Recruitment Status : Completed
First Posted : December 18, 2012
Last Update Posted : September 5, 2014
|First Submitted Date||December 11, 2012|
|First Posted Date||December 18, 2012|
|Last Update Posted Date||September 5, 2014|
|Study Start Date||December 2012|
|Actual Primary Completion Date||August 2013 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures
||PVAI and isolation of all non-PV triggers [ Time Frame: 1 hour of the ablation procedure ]
Isolation of pulmonary-vein antra and all extra-pulmonary vein triggers
|Original Primary Outcome Measures||Same as current|
|Change History||Complete list of historical versions of study NCT01751607 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures
||Recurrence of arrhythmia [ Time Frame: Within 1 year of follow-up ]
Recurrence will be defined as freedom from atrial flutter (AFL), AF or atrial tachycardia (AT) of > 30 seconds duration, in the absence of anti-arrhythmic drugs (AADs) at follow-up.
|Original Secondary Outcome Measures||Same as current|
|Current Other Outcome Measures||Not Provided|
|Original Other Outcome Measures||Not Provided|
|Brief Title||Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)|
|Official Title||Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)|
|Brief Summary||This prospective study aims to examine the association of specific genetic variants (single nucleotide polymorphisms) located on chromosome 1, 4 and 16, with presence of non-pulmonary vein triggers (NPVT) as well as ablation-outcome in AF patients|
Specific Aim: This prospective pilot study aims to examine the association of specific genetic variants (single nucleotide polymorphisms) namely rs2200733, rs6843082, rs10033464, rs17042171, rs2106261 and rs13376333 on chromosome 1, 4 and 16, with presence of non-pulmonary vein triggers (NPVT) as well as ablation-outcome in AF patients.
Hypothesis: Genetic variants predict prevalence of non-PV triggers as well as long-term procedure-outcome.
Background: Atrial fibrillation (AF) is the most common clinical arrhythmia affecting nearly 3.0 million people in the United States. Its significant contribution to population morbidity and mortality is amplified by the fact that AF is associated with 3-5 fold increase in the prevalence of cerebrovascular stroke and 2-fold increase in the risk of death. Limited efficacy of the available therapeutic strategies makes the matter worse; failures being attributed to lack of clear-understanding of the pathophysiology of this complex arrhythmia. In addition to the traditional risk factors including advancing age, obesity, metabolic syndrome, ischemic/valvular heart disease and hyperthyroidism etc that predict the occurrence of AF, genetic predisposition to AF has been reported in recent years.
Common AF often occurs with structural heart diseases but not all individuals with the same cardiac pathology develop AF, indicating that there must be genetic factors predisposing some individuals to AF. In 2007, the first Genome wide association study (GWAS) for AF in subjects of European descent was reported by investigators from Iceland. Two common variants on chromosome 4q25 were found that were strongly associated with AF. Following this initial report, several research groups provided independent replication analyses. So far, there are at least three distinct genomic loci, 4q25, 16q22, and 1q21 that have a strong association with AF.
Although an SNP is generally not sufficient to cause AF, it may act in combination with other SNPs or pathological conditions (e.g., ischemia and stretch) to increase susceptibility to AF or it may have some regulatory role in the expression of nearby genes that are potential candidate genes for AF.
Recent GWAS findings have left us with promising novel molecular pathways for AF and provide a starting point for the dissection of these novel pathways related to AF. However, the majority of these studies have not been replicated in independent populations or in different ethnic groups and none of the molecular pathways through which these SNPs lead to AF have been definitively determined. A better understanding and characterization of the genetic variants associated with AF in general population would facilitate new approaches to the diagnosis and efficient treatment of this arrhythmia.
On the other hand, catheter ablation has become an established invasive procedure treating patients with AF and has offered the promise to free patients of symptoms as well as eliminate the need for use of chronic drug therapy with agents that sometimes have significant risks, cost, and inconvenience for the patient. However, despite of the rapid progress of this technique in the past decade, the success rate and outcome of AF ablation remain suboptimal and largely variable depending on the case volume and ablation strategy used at individual centers. Many risk factors have been associated with the procedural failure and arrhythmia recurrence after AF ablation, including the type of AF, size of left atrium, cycle length of AF, etc. Recently, we have demonstrated that the presence of NPVT strongly predicts failure of AF ablation while elimination of NPVTs during the procedure significantly improves the long term freedom from arrhythmia after ablation of AF of any type. Non-PV triggers are defined as ectopic triggers originating from sites other than pulmonary veins such as left atrial posterior wall, superior vena cava, left atrial appendage, ligament of Marshall and coronary sinus.
Lately, a few published researches have shown that certain common genetic variants on different chromosomes are associated not only with an increased risk of AF itself, but also with the response to AF treatment or prognosis of AF patients. As we have observed a high incidence of NPVTs in AF patients and their role in determining the AF ablation outcome, we hypothesize that some common genetic variants at different chromosomal loci are associated with the occurrence of NPVTs, by which they subsequently predispose the development of AF and influence its response to management.
This prospective pilot study will enroll 400 consecutive AF patients undergoing catheter ablation. Baseline blood sample will be collected from all patients for genetic analysis. Quality of Life (QoL) surveys will be conducted at baseline and 1-year follow-up. All patients will be followed up for recurrence for one year.
The study will be conducted in collaboration with Dr. V. Iyer, professor at University of Texas at Austin. All genetic analyses will be performed at the UT core facility.
Association of SNPs with non-PV triggers was considered as primary endpoints.
1 ml of whole blood will be collected from each patient in a 4 ml Sodium-heparin tube before the ablation procedure. The blood sample will be labeled with an anonymous patient identifier that can only be identified by research staff. Following collection, blood sample will be stored at -200 C at the clinical lab of St. David's Medical Center until it is transferred (twice weekly in nitrogen bucket) to the lab of Dr. V. Iyer (Molecular Genetics and Microbiology, UT at Austin) where it will be stored at -70 degree C freezer until the end of the study, when all samples will be simultaneously analyzed. Genomic DNA purification and SNP analysis by Taqman assay will be performed for all samples at the end of the study, at the UT facility.
DNA purification protocol:
Qiagen QiaAMP 96 well blood kit will be used to lyse the white blood cells and purify genomic DNA.
Overview of the procedure for using TaqMan SNP Genotyping Assays:
Purified DNA samples will be used in a TaqMan qPCR assay. Briefly, a small quantity of each sample of DNA will be added to six wells in a 384 well qPCR plate. Next, Taqman fluorescent labeled probe will be added to the wells. Lastly, TaqMan master mix will be put in each well. This qPCR plate will be run on a Life Technologies ViiA7 real-time qPCR machine. To detect the presence or absence of each SNP in each patient, a plate reader will be used to detect fluorescence in each well.
Standard mapping and ablation procedures will be performed at the discretion of the physician.
Following ablation, patients will be discharged on their previously ineffective AADs which will be continued for 90 days (blanking period). The blanking period allows time for the inflammatory process to subside. AADs will be discontinued after the blanking period for all patients. If a patient suffers a recurrence of an atrial arrhythmia, AAD therapy may be administered at the discretion of the physician.
All patients will be followed-up for minimum of 1 year following the PVAI. Recurrence will be assessed by event recording for 5 months and Holter monitoring at 1, 3, 6 and 12 months. Recurrence will be defined as freedom from atrial flutter (AFL), AF or atrial tachycardia (AT) of > 30 seconds duration, in the absence of anti-arrhythmic drugs (AADs) at follow-up.
This study does not pose any additional risk to the patient. The risks are the same as those for a standard AF ablation.
Minor risks associated with a venous blood draw may include fainting or bruising, pain or discomfort and a 1/1000 risk of infection at the site where blood is drawn.
The subject may not incur any benefit by participating in this study.
Potential benefit for future patients: This information will enrich the knowledge about the molecular mechanism of AF and help in developing personalized ablation strategies for future patients that would be more effective in eliminating this arrhythmia.
Consecutive eligible patients will be approached for enrollment.
Continuous variables will be reported as mean ± standard deviation (SD). The categorical variables will be reported as frequencies and percentage. Data analysis will be performed using the unpaired Student's t-test for continuous variables and chi-square test for categorical variables.
For genotype-rhythm outcome correlations, 3 different models will be applied. The variant alleles will be assumed to be either dominant or recessive or having additive effects in these models. In the dominant model, an identical effect is expected in heterozygous and homozygous variant carriers. In the recessive model, an effect is only seen in homozygous variant carriers. Lastly, in the additive model, heterozygous variant carriers are assumed to have an intermediate effect as compared to the homozygotes.
Multivariate regression analysis will be performed using Cox proportional hazards model to test the association of the SNPs with the prevalence of non-PV triggers and outcome variable. SAS 9.2 (SAS Institute Inc., Cary, NC) will be used for statistical analysis
|Study Design||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration||Not Provided|
|Biospecimen||Retention: Samples With DNA
Blood samples will be collected from which DNA would be extracted for SNP analysis
|Sampling Method||Probability Sample|
|Study Population||patients with atrial fibrillation|
|Study Groups/Cohorts||genetic variants
AFib patients with or without the genetic variants
|Publications *||Mohanty S, Hall AW, Mohanty P, Prakash S, Trivedi C, Di Biase L, Santangeli P, Bai R, Burkhardt JD, Gallinghouse GJ, Horton R, Sanchez JE, Hranitzky PM, Al-Ahmad A, Iyer VR, Natale A. Novel association of polymorphic genetic variants with predictors of outcome of catheter ablation in atrial fibrillation: new directions from a prospective study (DECAF). J Interv Card Electrophysiol. 2016 Jan;45(1):7-17.|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Original Estimated Enrollment
|Actual Study Completion Date||August 2014|
|Actual Primary Completion Date||August 2013 (Final data collection date for primary outcome measure)|
|Ages||18 Years to 85 Years (Adult, Older Adult)|
|Accepts Healthy Volunteers||No|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||United States|
|Removed Location Countries|
|Other Study ID Numbers||TCAI_DECAF|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Andrea Natale, Texas Cardiac Arrhythmia Research Foundation|
|Study Sponsor||Texas Cardiac Arrhythmia Research Foundation|
|Collaborators||University of Texas at Austin|
|PRS Account||Texas Cardiac Arrhythmia Research Foundation|
|Verification Date||September 2014|